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Accepted 8 August 2013Allogeneic hematopoietic stem cell transplantation (HSCT)
is a potentially curative treatment option for patients with
hematologic malignancies and nonmalignant disorders of
hematopoiesis. Outcomes of allogeneic HSCT have improved
steadily over the decades [1]. However, signiﬁcant challenges
remain. One of these challenges is the so-called Holy Grail of
stem cell transplantation immunology: to preserve the bene-
ﬁcial effects of donor T cells against the tumor and against
pathogenswhile avoidingallogeneic graft-versus-host disease
(GVHD) [2]. To ﬁnd the Holy Grail, we must develop methods
or treatments that selectively deplete Tcells that react against
host alloantigens, yet preserve tumor-speciﬁc and pathogen-
reactive T cells. Experiments published by Ross et al. in this
issue of Biology of Blood and Marrow Transplantation [3]
suggest that post-transplantation cyclophosphamide (PTC),
a novel form of GVHD prophylaxis, may do just that.
PTC is celebrating its golden anniversary. In October 1963,
Berenbaum and Brown reported that cyclophosphamide (Cy)
treatment of rats prolonged the survival of skin allografts,
and that graft survival was longest when the drug was given
1 to 3 days after, rather than before, transplantation [4]. The
road to the use of PTC in allogeneic HSCT is long, but signif-
icant credit must be given to Hisanori Mayumi et al. in the
laboratory of Kikuo Nomoto [5]. These investigators devel-
oped a method for establishing hematopoietic micro-
chimerism and robust tolerance to minor histocompatibility
antigens in mice by i.v. infusion of allogeneic spleen cells
followed in 2 or 3 days by intraperitoneal administration of
high-dose Cy [6]. They showed that a high dose of cells was
required for tolerance induction, and that the dose and
timing of Cy were critical to the outcome [7]. For example,
tolerance and chimerismwere induced if the drugwere given
on day 2 or 3 after cell infusion, but not if the drugwere given
on day 1 or on day 4. Interestingly, Cy-induced tolerance was
blocked by peritransplantation treatment of the recipient
with cyclosporine A [8]. Finally, they showed that tolerance
of the microchimeric donor cells was mediated initially by
Cy-induced destruction of alloreactive host T cells, then by
intrathymic clonal deletion of donor-reactive host cells, andFinancial disclosure: See Acknowledgments on page 1414.
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http://dx.doi.org/10.1016/j.bbmt.2013.08.004later by the breakdown of clonal deletion and emergence of
donor-speciﬁc suppressor T cells in the periphery [9].
These initial studies aimed at generating tolerance to
solid organ allografts and focused primarily on the effects of
Cy on alloreactive T cells. In contrast, Ross et al. studied the
differential effects of the drug on alloreactive versus non-
alloreactive T cells infused into lethally conditioned recipi-
ents of syngeneic or allogeneic HSCT. By labeling donor
T cells with the intravital dye carboxyﬂuorescein succini-
midyl ester, they were able to study the toxicity of the drug
according to the number of divisions a cell had undergone
in vivo. After allogeneic HSCT, a dose of Cy that prevented
GVHD (33 mg/kg each on days 3 and 4) killed the vast
majority of cells that had dividedmore than 2 times, and only
2 to 3 generations of early dividing cells remained. In
contrast, after syngeneic HSCT, donor cells underwent slow,
lymphopenia-induced proliferation (LIP), and most of these
cells survived the same dose of Cy. The authors then tracked
the fate of ovalbumin-speciﬁc (OT-1) or melanoma antigen
gp100-speciﬁc transgenic T cells undergoing lymphopenia-
or antigen-induced proliferation. Cells responding to lym-
phopenia proliferated slowly andwere largely resistant to Cy,
whereas the same cells responding to antigen proliferated
rapidly and were killed by Cy given on day 3 and 4. Finally,
OT-1 cells were coinfused with alloreactive cells into lethally
irradiated allogeneic recipients. PTC abrogated GVHD and
enhanced reconstitution of the OT-1 cells, suggesting that
a cytotoxic and immunosuppressive drug can actually
improve immune reconstitution after allogeneic HSCT.
TheworkbyRosset al. is important for several reasons. First,
it raises the possibility that a T cell’s sensitivity to being killed
byCy is determinedby its rate of proliferation. Second, it shows
that LIP does not render a T cell susceptible to Cy-induced
death. Finally, and perhaps most importantly, the work
provides the ﬁrst demonstration of selective in vivo allode-
pletion, placing the Holy Grail of stem cell transplantation
immunology ﬁrmly in sight of clinicians. Indeed, after estab-
lishing its utility in preventing GVHD after allogeneic HSCT in
humans [10,11], PTC is returning to the ﬁeld of solid organ
transplantation, helping to promote immunosuppression-free
tolerance to combined kidneyandbonemarrowallografts [12].
Still, important questions remain unanswered. When
transplant donors are primed to host alloantigens 1 week
before allogeneic HSCT, the donor T cells resist PTC and
induce lethal GVHD [13]. Are alloantigen-primed donor
Tcells able to resist PTC because they proliferatemore slowly,
or have they acquired additional mechanisms of drug resis-
tance? Does LIP protect cells from Cy-induced tolerance, or
would non-alloreactive cells resist Cy-induced killing in
immunocompetent, i.e. non-lymphopenic, hosts? Finally,
what is the fate of leukemia-speciﬁc, as opposed to allor-
eactive, T cells that are infused into an animal with minimal
N.S. Majhail, H.M. Lazarus / Biol Blood Marrow Transplant 19 (2013) 1413e14151414residual disease and then exposed to PTC? These and other
questions should provide a hearty agenda for future research.
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Accepted 29 July 2013Many within the transplantation community perceive
that allogeneic hematopoietic cell transplantation (HCT) is
an underutilized approach among appropriate adult patients
who potentially may beneﬁt from this procedure. This
perception is particularly true for patients who do not have
an HLA-identical sibling donor and for whom the graft must
come from unrelated donors or umbilical cord blood (UCB)
units (henceforth, both are referred to as URD). In this issue,
Yao et al. [1] present a study that quantiﬁes this view; after
accounting for comorbidities, pretransplantation treatment
mortality, and patient preferences, only one quarter of
patients in whom URD HCT is indicated actually receive it.
The utilization for speciﬁc diseases ranged from 11% for
myeloma to 54% for chronic myeloid leukemia, 2 diseases for
which indications for HCT have dropped. In the present era,when it appears that nearly all patients can ﬁnd a suitable
donor for transplantation, including haploidentical HCT [2],
this low percentage is a staggering statistic. Further, Yao et al.
[1] show that among acute leukemia patients, two thirds
underwent transplantation only in late stage disease, a point
in time when survival outcomes are inferior when compared
with earlier use of HCT [3,4].
The National Marrow Donor Program (NMDP) has access
to 21 million potential donors worldwide, including 11
million through its Be The Match Registry. This potential
graft inventory also includes more than 600,000 cry-
opreserved UCB units. The likelihood of identifying an adult
donor, unfortunately, reﬂects race, as white patients have
a 93% likelihood of ﬁnding a match, whereas for minority
ethnic and racial groups, the chance is less; the lowest like-
lihood is for blacks, at 66%. On the other hand, a suitable UCB
unit can be found for transplantation for most patients in
whom a matched adult donor cannot be found. The NMDP
estimates that approximately 12,000 patients in the United
States need an URD transplantation each year. An early step
in this process is the initiation of a “formal search”, which
usually indicates a deﬁnitive intent on behalf of the trans-
plantation center to move ahead with an URD HCT. In the
2012 ﬁscal year, a formal search was requested for only 7400
patients, just 62% of the need. Furthermore, only 60% of
patients for whom a formal search was initiated actually
proceeded to transplantation.
